A carregar...
Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
In the early 2000s, the anticancer drug imatinib (Glivec®) appeared on the market, exhibiting a new mode of action by selective kinase inhibition. Consequently, kinases became a validated therapeutic target, paving the way for further developments. Although these kinases have been thoroughly studied...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2014-09-01
|
| Colecção: | Molecules |
| Assuntos: | |
| Acesso em linha: | http://www.mdpi.com/1420-3049/19/9/14366 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|